Literature DB >> 36136254

Tumor doubling time as preoperative predictor of malignancy and recurrence in newly diagnosed meningioma.

Yusuke Miwa1, Takashi Sugawara2, Daisuke Kobayashi3, Taketoshi Maehara1.   

Abstract

Most meningiomas are benign, and the indications for surgery are determined by size and symptoms, but some are malignant and have a high recurrence rate. Currently, no preoperative prognostic factors have been established. The purpose of this study was to investigate whether tumor doubling time (Td) is useful in predicting tumor prognosis. Patients who underwent surgery for newly diagnosed meningioma at our hospital between 2007 and 2021 with preoperative magnetic resonance (MR) imaging evaluation over a period of 6 months were included in this study. We calculated the Td from the preoperative MR images and examined the correlation between Td and WHO grade, MIB-1 SI, and other conditions. A total of 269 newly diagnosed meningiomas were operated on during the study period, of which 62 met inclusion criteria. The median Td was 1082 days (54-8579 days), and MIB-1 SI was 2.45% (0.7-14.6%). Td and MIB-1 SI had a negative correlation (r =  - 0.319, p = 0.0122). MIB-1 SI was higher in patients with Td < 3 years than in those with Td ≥ 3 (p = 0.005), and the incidence of high WHO grade (grade2) was higher in patients with Td < 1 year than in patients with Td ≥ 1 (p = 0.014). Meningiomas with Td < 3 years had significantly higher MIB-1 SI, and tumors with Td < 1 year had a higher likelihood of malignancy. Therefore, early treatment should be considered in patients with short Td meningioma even if asymptomatic, and further consideration could be given to radical resection at the time of surgery.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  MIB-1 SI; Meningioma; Recurrence; Risk factor; Tumor doubling time

Year:  2022        PMID: 36136254     DOI: 10.1007/s10143-022-01869-2

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   2.800


  7 in total

1.  Trends in Management of Intracranial Meningiomas: Analysis of 49,921 Cases from Modern Cohort.

Authors:  Vijay Agarwal; Brandon A McCutcheon; Joshua D Hughes; Matthew L Carlson; Amy E Glasgow; Elizabeth B Habermann; Quoc-Bao Nguyen; Michael J Link; Jamie J Van Gompel
Journal:  World Neurosurg       Date:  2017-06-27       Impact factor: 2.104

2.  Growth curve analysis of asymptomatic and symptomatic meningiomas.

Authors:  Satoshi Nakasu; Yoko Nakasu; Tadateru Fukami; Junya Jito; Kazuhiko Nozaki
Journal:  J Neurooncol       Date:  2010-08-05       Impact factor: 4.130

Review 3.  Incidental meningiomas.

Authors:  Roukoz Chamoun; Khaled M Krisht; William T Couldwell
Journal:  Neurosurg Focus       Date:  2011-12       Impact factor: 4.047

4.  Significance of Simpson grading system in modern meningioma surgery: integration of the grade with MIB-1 labeling index as a key to predict the recurrence of WHO Grade I meningiomas.

Authors:  Soichi Oya; Kensuke Kawai; Hirofumi Nakatomi; Nobuhito Saito
Journal:  J Neurosurg       Date:  2012-05-04       Impact factor: 5.115

5.  Slower growth of skull base meningiomas compared with non-skull base meningiomas based on volumetric and biological studies.

Authors:  Naoya Hashimoto; Carter S Rabo; Yoshiko Okita; Manabu Kinoshita; Naoki Kagawa; Yasunori Fujimoto; Eiichi Morii; Haruhiko Kishima; Motohiko Maruno; Amami Kato; Toshiki Yoshimine
Journal:  J Neurosurg       Date:  2011-12-16       Impact factor: 5.115

6.  Potential doubling time and tumour doubling time in meningiomas and neurinomas.

Authors:  S Nakasu; Y Nakasu; M Nakajima; M Yokoyama; M Matsuda; J Handa
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

7.  Investigation of the freely available easy-to-use software 'EZR' for medical statistics.

Authors:  Y Kanda
Journal:  Bone Marrow Transplant       Date:  2012-12-03       Impact factor: 5.483

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.